EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy

In this segment, Dr. Sands asks Dr. Cooper to discuss how she evaluates key efficacy outcomes when selecting first-line therapy for EGFR-mutated non-small cell lung cancer. Dr. Cooper emphasizes the importance of considering multiple endpoints, including progression-free survival, overall survival, and central nervous system activity, rather than relying on a single metric. She highlights how CNS efficacy is particularly critical given the high incidence of brain metastases in this patient population. The discussion also touches on how patient-specific factors, such as disease burden, mutation subtype, and overall prognosis, influence treatment selection. Dr. Cooper underscores the need to contextualize clinical trial data within real-world practice, balancing the depth and durability of response with long-term outcomes. Overall, this segment provides insight into how clinicians interpret and prioritize efficacy data to guide individualized first-line treatment decisions in EGFR-mutated NSCLC.